1310877-29-2Relevant academic research and scientific papers
Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond to Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain
Fuchino, Kouki,Mitsuoka, Yasunori,Masui, Moriyasu,Kurose, Noriyuki,Yoshida, Shuhei,Komano, Kazuo,Yamamoto, Takahiko,Ogawa, Masayoshi,Unemura, Chie,Hosono, Motoko,Ito, Hisanori,Sakaguchi, Gaku,Ando, Shigeru,Ohnishi, Shuichi,Kido, Yasuto,Fukushima, Tamio,Miyajima, Hirofumi,Hiroyama, Shuichi,Koyabu, Kiyotaka,Dhuyvetter, Deborah,Borghys, Herman,Gijsen, Harrie J.M.,Yamano, Yoshinori,Iso, Yasuyoshi,Kusakabe, Ken-Ichi
supporting information, p. 5122 - 5137 (2018/05/23)
Accumulation of Aβ peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD. β-Secretase (BACE1) is a key enzyme responsible for producing Aβ peptides, and thus agents that inhibit BACE1 should be bene
FUSED AMINODIHYDROPYRIMIDINE DERIVATIVE
-
Paragraph 0234; 0235, (2013/08/28)
The present invention provides, for example, the following compound: wherein ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, X1—X2═X3 is CR5—CR6═CRs
OXAZINE DERIVATIVES
-
Page/Page column 52, (2012/10/08)
The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins. A compound of the formula (I): wherein R1, Rs
